Myriad published the results of their phase II study in The Lancet in late April. Flurizan (tarenflurbil) is a SALA (selective amyloid lowering agent) that is hypothesized to reduce the formation of brain-cell destroying beta amyloid plaques. The results of the study indicated that patients on Flurizan did better on some, but not all, measures of the progression of Alzheimer’s disease. Moreover, the benefit was apparent only in patients who started the medication while in the early stages of the disease. Based upon these finding, Myriad is now testing Flurizan in a larger phase III study that is limited to patients with very mild disease. It is these data that will be presented at ICAD. If the results of this study are positive, it is possible that Flurizan could be the first drug approved by the FDA for treatment of disease progression in AD.
I will report back on the findings and implications of both the vaccine study and the Flurizan study when I return from ICAD at the end of July.
- Font size
- Email This
- Bookmark
- Thank you for your input
- Save
- RSS
- Report Abuse
